Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bon Health vs Garcia Weight Loss, Aesthetics & Hormone Therapy

Bon Health
Graded #113

Higher grade

vs+10.300000000000004

The verdict

Bon Health takes it — 69.7/100 to 59.4/100.

Bon Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bon Health is a physician-led GLP-1 weight-loss telehealth service selling compounded semaglutide and tirzepatide on commitment tiers.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBon Health +45
75
30
Dose & formulationBon Health +12
64
52
Clinical oversightBon Health +6
85
79
Labs & monitoringGarcia Weight Loss, Aesthetics & Hormone Therapy +42
55
97
FulfillmentBon Health +16
72
56
Contract termsGarcia Weight Loss, Aesthetics & Hormone Therapy +2
53
55
Bon Health · left barGarcia Weight Loss, Aesthetics & Hormone Therapy · right bar

The numbers

MetricBon HealthGarcia Weight Loss, Aesthetics & Hormone Therapy
WeighScore69.7/10059.4/100
GradeCC
Scorecard rank#113#342
Semaglutide$120/mo (12-month plan, compounded)$400/mo (starting dose, compounded)
Tirzepatide$170/mo (12-month plan, compounded)Not disclosed
CoverageCoverage not published1 state
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Bon Health

Graded #113 · C

Strengths

  • Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
  • Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
  • 24/7 physician support included free with your order; 1-3 day rapid dispatch
  • Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered

Where it loses points

  • The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
  • The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
  • Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
  • The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Strengths

  • Established since 2000 with 4 Tampa Bay locations and 50,000+ patients treated
  • GLP-1 program includes full metabolic and hormone lab panel
  • Medication and supplies shipped directly to your door from partner pharmacy
  • Free 15-minute consultation; both weekly-visit (Premier) and monthly-visit (Standard) tiers
  • LegitScript transparency certification listed in footer

Where it loses points

  • Florida only — 4 locations in Tampa Bay metro area only
  • Pricing not publicly listed on website ($400/month per Facebook ad)
  • Specific GLP-1 drug (semaglutide vs tirzepatide) not disclosed on site
  • Telemedicine availability not confirmed on site despite Facebook ad claims
  • In-person visit model less convenient than fully online telehealth providers

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard